CLINICAL STUDIES
European multicenter study on propionyl-L-carnitine in intermittent claudication
Gregorio Brevetti, MD*,
Curt Diehm, MD ,
David Lambert, MD on behalf of the Study Investigators
* Department of Medicine, University Federico II, Napoli, Italy
Klinikum Karlsbad-Langensteinbach, Karlsbad-Langenfeld, Germany
Freeman Hospital, Newcastle-Upon Tyne, United Kingdom
Manuscript received June 18, 1998;
revised manuscript received May 12, 1999,
accepted June 29, 1999.
Reprint requests and correspondence: Dr. Gregorio Brevetti, Via G.Iannelli 45/a, 80131 Napoli, Italy
brevetti{at}unina.it
OBJECTIVES
This study was performed to identify a target population of claudicants for propionyl-L-carnitine treatment.
BACKGROUND
Previous studies suggest that the efficacy of propionyl-L-carnitine in intermittent claudication is greater in patients with severe functional impairment than in those with mild walking disability.
METHODS
After run-in, 485 claudicant patients were randomized to placebo or propionyl-L-carnitine (1 g bid, po) and then stratified on the basis of maximal walking distance (cutoff point 250 m) and maximal walking distance variability (cutoff point 25%). Treatment lasted 12 months. Walking capacity was assessed by treadmill and quality of life by a questionnaire exploring various aspects of daily life.
RESULTS
In the target population, that is, patients who at baseline walked  250 m and showed a maximal walking distance variability 25%, per-protocol analysis showed that the effect of propinyl-L-carnitine was significantly greater than that with placebo for both maximal walking distance and initial claudication distance (ICD). In the intention-to-treat population, maximal walking distance increased by 62 ± 14% on propionyl-L-carnitine and by 46 ± 9% (p < 0.05) on placebo, while no difference between treatments was observed for ICD. The beneficial effect of propionyl-L-carnitine was confirmed when data of the target population were pooled with those of patients who at baseline walked 250 m and showed a >25% maximal walking distance <50% variability. Actually, maximal walking distance increased by 98 ± 16% in the propionyl-L-carnitine group and by only 54 ± 10% in the placebo group (p < 0.01). The corresponding values for ICD were 99 ± 21% and 51 ± 8% (p < 0.05). For patients with baseline maximal walking distance >250 m, no difference between treatments was observed.
CONCLUSIONS
Claudicants with maximal walking distance 250 m benefited from the use of propionyl-L-carnitine, with improvement in walking distance and quality of life. However, patients with mild functional impairment (i.e., walking distance >250 m) showed no response to propionyl-L-carnitine.
|
Abbreviations and Acronyms
| | ABPI | = ankle-brachial pressure index | | ICD | = initial claudication distance | | MWD | = maximum walking distance |
|
This article has been cited by other articles:
|
|
|
|
 
G. M. Andreozzi, A. Leone, R. Laudani, R. Martin, G. Deinit, and V. Cataldi
Levo-Propionyl-Carnitine Improves the Effectiveness of Supervised Physical Training on the Absolute Claudication Distance in Patients With Intermittent Claudication
Angiology,
March 1, 2008;
59(1):
84 - 89.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. P. Brass, J. Jiao, and W. Hiatt
Optimal assessment of baseline treadmill walking performance in claudication clinical trials
Vascular Medicine,
May 1, 2007;
12(2):
97 - 103.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Orlandi, A. Francesconi, M. Marcellini, A. Di Lascio, and L. G. Spagnoli
Propionyl-L-carnitine Reduces Proliferation and Potentiates Bax-related Apoptosis of Aortic Intimal Smooth Muscle Cells by Modulating Nuclear Factor-{kappa}B Activity
J. Biol. Chem.,
February 16, 2007;
282(7):
4932 - 4942.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. P Brass and W. R Hiatt
Review of mortality and cardiovascular event rates in patients enrolled in clinical trials for claudication therapies
Vascular Medicine,
August 1, 2006;
11(3):
141 - 145.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L Norgren, A Jawien, L Matyas, H Rieger, K Arita, and European MCI-9042 Study Group
Sarpogrelate, a 5-HT2A receptor antagonist in intermittent claudication. A Phase II European study
Vascular Medicine,
May 1, 2006;
11(2):
75 - 83.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Silvestro, V. Schiano, R. Bucur, G. Brevetti, F. Scopacasa, and M. Chiariello
Effect of Propionylcarnitine on Changes in Endothelial Function and Plasma Levels of Adhesion Molecules Induced by Acute Exercise in Patients with Intermittent Claudication
Angiology,
March 1, 2006;
57(2):
145 - 154.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. J. Hankey, P. E. Norman, and J. W. Eikelboom
Medical Treatment of Peripheral Arterial Disease
JAMA,
February 1, 2006;
295(5):
547 - 553.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. K. Patel
The Role of Nutrition in the Management of Lower Extremity Wounds
International Journal of Lower Extremity Wounds,
March 1, 2005;
4(1):
12 - 22.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Casey, B. H. Tonnessen, W. C. Sternbergh III, and S. R. Money
Medical Management of Intermittent Claudication
Vascular and Endovascular Surgery,
September 1, 2004;
38(5):
391 - 399.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Rajagopalan, E. R. Mohler III, R. J. Lederman, F. O. Mendelsohn, J. F. Saucedo, C. K. Goldman, J. Blebea, J. Macko, P. D. Kessler, H. S. Rasmussen, et al.
Regional Angiogenesis With Vascular Endothelial Growth Factor in Peripheral Arterial Disease: A Phase II Randomized, Double-Blind, Controlled Study of Adenoviral Delivery of Vascular Endothelial Growth Factor 121 in Patients With Disabling Intermittent Claudication
Circulation,
October 21, 2003;
108(16):
1933 - 1938.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M Dean
Pharmacologic treatment for intermittent claudication
Vascular Medicine,
November 1, 2002;
7(4):
301 - 309.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. R. Jaff
Pharmacotherapy for Peripheral Arterial Disease: Emerging Therapeutic Options
Angiology,
November 1, 2002;
53(6):
627 - 633.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Coccheri, G. Scondotto, G. Agnelli, E. Palazzini, and V. Zamboni
Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study
Eur. Heart J.,
July 1, 2002;
23(13):
1057 - 1065.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Condorelli and G. Brevetti
Intermittent claudication: an historical perspective
Eur. Heart J. Suppl.,
March 1, 2002;
4(suppl_B):
B2 - B7.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Perrone-Filardi and M. Chiariello
Coronary artery disease and intermittent claudication: how to manage the patient
Eur. Heart J. Suppl.,
March 1, 2002;
4(suppl_B):
B58 - B62.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. T Cooper Jr, W. R Hiatt, M. A Creager, J. G Regensteiner, W. Casscells, J. M Isner, J. P Cooke, and A. T Hirsch
Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication
Vascular Medicine,
November 1, 2001;
6(4):
235 - 239.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. R. Hiatt
Medical Treatment of Peripheral Arterial Disease and Claudication
N. Engl. J. Med.,
May 24, 2001;
344(21):
1608 - 1621.
[Full Text]
[PDF]
|
|
|
|
